BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang H, Chen P. The potential and challenges of CRISPR-Cas in eradication of hepatitis B virus covalently closed circular DNA. Virus Research 2018;244:304-10. [DOI: 10.1016/j.virusres.2017.06.010] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
Number Citing Articles
1 Martinez MG, Smekalova E, Combe E, Gregoire F, Zoulim F, Testoni B. Gene Editing Technologies to Target HBV cccDNA. Viruses 2022;14. [PMID: 36560658 DOI: 10.3390/v14122654] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Bhat SA, Kazim SN. HBV cccDNA─A Culprit and Stumbling Block for the Hepatitis B Virus Infection: Its Presence in Hepatocytes Perplexed the Possible Mission for a Functional Cure. ACS Omega. [DOI: 10.1021/acsomega.2c02216] [Reference Citation Analysis]
3 Watanabe T, Hayashi S, Tanaka Y. Drug Discovery Study Aimed at a Functional Cure for HBV. Viruses 2022;14:1393. [DOI: 10.3390/v14071393] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Murai K, Kodama T, Hikita H, Shimoda A, Fukuoka M, Fukutomi K, Shigeno S, Shiode Y, Motooka D, Higuchi Y, Miyakawa K, Suemizu H, Ryo A, Tahata Y, Makino Y, Yamada R, Sakamori R, Tatsumi T, Takehara T. Inhibition of nonhomologous end joining-mediated DNA repair enhances anti-HBV CRISPR therapy. Hepatol Commun 2022. [PMID: 35608131 DOI: 10.1002/hep4.2014] [Reference Citation Analysis]
5 Yang YC, Yang HC. Recent Progress and Future Prospective in HBV Cure by CRISPR/Cas. Viruses 2021;14:4. [PMID: 35062208 DOI: 10.3390/v14010004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
6 Miao J, Gao P, Li Q, He K, Zhang L, Wang J, Huang L. Advances in Nanoparticle Drug Delivery Systems for Anti-Hepatitis B Virus Therapy: A Narrative Review. Int J Mol Sci 2021;22:11227. [PMID: 34681886 DOI: 10.3390/ijms222011227] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Pisano MB, Giadans CG, Flichman DM, Ré VE, Preciado MV, Valva P. Viral hepatitis update: Progress and perspectives . World J Gastroenterol 2021; 27(26): 4018-4044 [PMID: 34326611 DOI: 10.3748/wjg.v27.i26.4018] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
8 Hirakawa MP, Krishnakumar R, Timlin JA, Carney JP, Butler KS. Gene editing and CRISPR in the clinic: current and future perspectives. Biosci Rep 2020;40:BSR20200127. [PMID: 32207531 DOI: 10.1042/BSR20200127] [Cited by in Crossref: 87] [Cited by in F6Publishing: 90] [Article Influence: 43.5] [Reference Citation Analysis]
9 Yang Y, Xu J, Ge S, Lai L. CRISPR/Cas: Advances, Limitations, and Applications for Precision Cancer Research. Front Med (Lausanne) 2021;8:649896. [PMID: 33748164 DOI: 10.3389/fmed.2021.649896] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 7.5] [Reference Citation Analysis]
10 Rong X, Ailing F, Xiaodong L, Jie H, Min L. Monitoring hepatitis B by using point-of-care testing: biomarkers, current technologies, and perspectives. Expert Rev Mol Diagn 2021;21:195-211. [PMID: 33467927 DOI: 10.1080/14737159.2021.1876565] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Bassit L, Ono SK, Schinazi RF. Moving Fast Toward Hepatitis B Virus Elimination. Adv Exp Med Biol 2021;1322:115-38. [PMID: 34258739 DOI: 10.1007/978-981-16-0267-2_5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Li FC, Li YK, Fan YC. Biomarkers for hepatitis B virus replication: an overview and a look to the future. Expert Rev Gastroenterol Hepatol 2020;14:1131-9. [PMID: 32887529 DOI: 10.1080/17474124.2020.1815530] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
13 Soriano V, Barreiro P, Cachay E, Kottilil S, Fernandez-Montero JV, de Mendoza C. Advances in hepatitis B therapeutics. Ther Adv Infect Dis 2020;7:2049936120965027. [PMID: 33117536 DOI: 10.1177/2049936120965027] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
14 Zheng N, Li L, Wang X. Molecular mechanisms, off-target activities, and clinical potentials of genome editing systems. Clin Transl Med 2020;10:412-26. [PMID: 32508055 DOI: 10.1002/ctm2.34] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
15 Yang YC, Chen YH, Kao JH, Ching C, Liu IJ, Wang CC, Tsai CH, Wu FY, Liu CJ, Chen PJ, Chen DS, Yang HC. Permanent Inactivation of HBV Genomes by CRISPR/Cas9-Mediated Non-cleavage Base Editing. Mol Ther Nucleic Acids. 2020;20:480-490. [PMID: 32278307 DOI: 10.1016/j.omtn.2020.03.005] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 14.0] [Reference Citation Analysis]
16 Tao Y, Wu D, Zhou L, Chen E, Liu C, Tang X, Jiang W, Han N, Li H, Tang H. Present and Future Therapies for Chronic Hepatitis B. Adv Exp Med Biol. 2020;1179:137-186. [PMID: 31741336 DOI: 10.1007/978-981-13-9151-4_6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
17 Ramos CL, de Figueiredo Vilela L, Schwan RF. Genetic Engineering as a Driver for Biotechnological Developments and Cloning Tools to Improve Industrial Microorganisms. Bioprocessing for Biomolecules Production 2019. [DOI: 10.1002/9781119434436.ch13] [Reference Citation Analysis]
18 Soriano V, Aguilera A, Gonzalez R, Gomez-Gallego F, Barea L, Treviño M, Corral O. Occult hepatitis B and HIV infection. Eur J Gastroenterol Hepatol 2019;31:1403-7. [PMID: 30969194 DOI: 10.1097/MEG.0000000000001417] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
19 Bellizzi A, Ahye N, Jalagadugula G, Wollebo HS. A Broad Application of CRISPR Cas9 in Infectious Diseases of Central Nervous System. J Neuroimmune Pharmacol 2019;14:578-94. [PMID: 31512166 DOI: 10.1007/s11481-019-09878-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
20 Zhu A, Liao X, Li S, Zhao H, Chen L, Xu M, Duan X. HBV cccDNA and Its Potential as a Therapeutic Target. J Clin Transl Hepatol 2019;7:258-62. [PMID: 31608218 DOI: 10.14218/JCTH.2018.00054] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
21 Lee C. CRISPR/Cas9-Based Antiviral Strategy: Current Status and the Potential Challenge. Molecules 2019;24:E1349. [PMID: 30959782 DOI: 10.3390/molecules24071349] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 6.8] [Reference Citation Analysis]
22 Loesch R, Desbois-Mouthon C, Colnot S. Potentials of CRISPR in liver research and therapy. Clin Res Hepatol Gastroenterol 2019;43:5-11. [PMID: 29884474 DOI: 10.1016/j.clinre.2018.05.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
23 Coffin CS, Zhou K, Terrault NA. New and Old Biomarkers for Diagnosis and Management of Chronic Hepatitis B Virus Infection. Gastroenterology 2019;156:355-368.e3. [PMID: 30472225 DOI: 10.1053/j.gastro.2018.11.037] [Cited by in Crossref: 69] [Cited by in F6Publishing: 71] [Article Influence: 17.3] [Reference Citation Analysis]
24 Kostyusheva A, Kostyushev D, Brezgin S, Volchkova E, Chulanov V. Clinical Implications of Hepatitis B Virus RNA and Covalently Closed Circular DNA in Monitoring Patients with Chronic Hepatitis B Today with a Gaze into the Future: The Field Is Unprepared for a Sterilizing Cure. Genes (Basel) 2018;9:E483. [PMID: 30301171 DOI: 10.3390/genes9100483] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
25 de Buhr H, Lebbink RJ. Harnessing CRISPR to combat human viral infections. Current Opinion in Immunology 2018;54:123-9. [DOI: 10.1016/j.coi.2018.06.002] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
26 Mohebbi A, Lorestani N, Tahamtan A, Kargar NL, Tabarraei A. An Overview of Hepatitis B Virus Surface Antigen Secretion Inhibitors. Front Microbiol 2018;9:662. [PMID: 29675010 DOI: 10.3389/fmicb.2018.00662] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
27 Shen F, Sergi C, Sun HL. Hepatitis B Virus Covalently Closed Circular DNA-Selective Droplet Digital PCR: A Sensitive and Noninvasive Method for Hepatocellular Carcinoma Diagnosis? J Mol Diagn. 2018;20:277-278. [PMID: 29572198 DOI: 10.1016/j.jmoldx.2018.03.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
28 Liu Y, Zhao M, Gong M, Xu Y, Xie C, Deng H, Li X, Wu H, Wang Z. Inhibition of hepatitis B virus replication via HBV DNA cleavage by Cas9 from Staphylococcus aureus. Antiviral Res 2018;152:58-67. [PMID: 29458131 DOI: 10.1016/j.antiviral.2018.02.011] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 8.2] [Reference Citation Analysis]
29 Mak L, Wong DK, Seto W, Lai C, Yuen MF. Hepatitis B core protein as a therapeutic target. Expert Opinion on Therapeutic Targets 2017;21:1153-9. [DOI: 10.1080/14728222.2017.1397134] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 4.5] [Reference Citation Analysis]